Christian Marsolais

Company: Theratechnologies Inc.

Job title: Senior Vice President & Chief Medical Officer

Seminars:

Targeting Sortilin (SORT1) to Unlock the Potential of Peptide Drug Conjugates (PDCs) in Oncology: Rapid Internalization and Improved Tumor Penetration Within Minutes 9:00 am

Understand the rationale for targeting the SORT1 receptor in cancer Discuss the preclinical as well as the emerging clinical data of sudocetaxel zendusortide (TH1902), the lead PDC from Theratechnologies’ SORT1+ Technology™ platform Discuss the unique multimodal MOA of this PDC Explore the potential of SORT1+ Technology™ for future developments, such as novel PDC’s and combinationsRead more

day: Conference Day One AM